In-Part Discover: Development of Novel Drugs for the Modulation of Innate Lymphoid Cells (ILCs)

A global pharmaceutical company with a history of successful academic collaborations and cutting-edge capabilities in drug development is looking for research collaboration or funding proposals involving new drug discovery programs related to innate lymphoid cells (ILCs). Our client wishes to fund projects up to €750k (or $830k if based in North America), focussing on the development of novel drugs and technologies to modulate ILCs.

Deadline: February 24, 2020

More information.